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Objective: Carotid artery stenting (CAS) for treatment of carotid stenosis has not received wide acceptance because of the
availability of carotid endarterectomy (CEA) with its excellent results and because of the risk of embolic stroke associated
with CAS. The feasibility and efficacy of cerebral protection devices that may prevent such embolic complications have yet
to be shown. We report our initial results with CAS performed with cerebral protection.
Methods: For a period of 28 months, 31 patients with carotid artery stenosis, most of whom were considered at high risk
for CEA (87%), underwent treatment with CAS in conjunction with either the PercuSurge GuardWire (n  19;
Medtronic, Minneapolis, Minn), the Cordis Angioguard filter (n  7; Cordis, Warren, NJ), or the ArteriA Parodi
Anti-embolization catheter (n  4; ArteriA, San Francisco, Calif) with US Food and Drug Administration–approved
investigational device exemptions. Factors that made CEA high risk included restenosis after CEA (n  6), hostile neck
(n 6), high or low lesions (n 4), and severe comorbid medical conditions (n 11). Preoperative neurologic symptoms
were present in 58%, and the mean stenosis was 85%  12%. Data were prospectively recorded and analyzed on an
intent-to-treat basis. Neurologic evaluation was performed before and after CAS by a protocol neurologist.
Results: CAS was performed with local anesthesia with the Wallstent (n  23; Boston Scientific Corp, Natick, Mass) or
the PRECISE carotid stent (n  7; Cordis) in conjunction with one of the protection devices in an operating room with
a mobile C-arm. Each patient received dual antiplatelet therapy before surgery. The overall technical success rate was 97%
(30/31). In one patient, the lesion could not be crossed with a guidewire because of a severely stenosed and tortuous
lesion. This patient was not a candidate for CEA and was treated conservatively. In the remaining 30 cases, CAS had a good
angiographic result (residual stenosis, <10%). All patients tolerated the protection device well, and no intraprocedural
neurologic complications occurred. Macroscopic embolic particles were recovered from each case. One patient (3%) with a
severely tortuous vessel had a major stroke immediately after CAS, and no deaths occurred. The combined 30 day stroke/death
rate was 3%. During a mean follow-up period of 17 months, one subacute occlusion of the stent occurred but did not result
in a stroke. Three other patients had duplex scan–proven instent restenosis, and two underwent treatment with repeat
percutaneous transluminal angioplasty with a good result. No patient had a stroke during the follow-up period.
Conclusion: CAS with cerebral protection devices can be performed safely with a high technical success rate. Although
many patients who underwent treatment with CAS were at high risk, the neurologic complication rate was low and CAS
appears to be an acceptable treatment option for select patients at high risk for CEA. Tight lesions and tortuous anatomy
may make the use of distal protection devices difficult. Further study is warranted. (J Vasc Surg 2002;36:1175-85.)
Stroke is the third leading cause of death in the United
States, with 1.5 deaths reported per 1000 persons. Carotid
endarterectomy (CEA) is the “gold standard” treatment to
reduce the risk of stroke in most patients with significant
carotid artery occlusive disease, and this has been docu-
mented by multicenter, randomized, controlled trials.1-6
However, CEA is not perfect and room for improvement
remains. Complications related to CEA include periopera-
tive myocardial infarction, stroke, cranial nerve injury, and
wound problems, which have been reported at cumulative
rates ranging between 12% and 21%.1-6 In addition,
certain groups of patients are deemed to be at high risk
for CEA. These patients include those with severe comorbid
conditions or a hostile neck from previous surgery (includ-
ing CEA), radiation therapy, and the presence of a tracheos-
tomy.7,8 Although some studies have reported good results
in this group of patients, outcome of CEA is not always
satisfactory.
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Carotid artery stenting (CAS) has recently emerged as
an alternative to CEA. Although good results have been
reported from several centers,9-15 concerns regarding the
safety and efficacy of CAS have been raised, and its general
role and comparative value remain unclear.16-23 One major
concern has been the potential for CAS to produce embolic
particles that may manifest as a neurologic deficit.20,21,24
Several devices have recently been developed that can cap-
ture these embolic particles and potentially reduce periop-
erative complications.25-27 We report our initial experience
with the use of three different types of cerebral protection
devices during CAS.
METHODS
Patients. Between October 1999 and March 2002, 31
patients with severe carotid artery stenosis, most of whom
(27/31; 87%) were deemed at high risk or contraindicated
for CEA, were enrolled into one of three US Food and
Drug Administration–approved investigational device ex-
emption clinical trials. Before access to cerebral protection
devices, CAS was seldom performed at our institution
because of concerns regarding embolization. These trials
included: 1, an investigator sponsored protocol involving
the use of the PercuSurge GuardWire (Medtronic, Minne-
apolis, Minn) and the Wallstent (Boston Scientific Corp,
Natick, Mass), which later became the SHELTER (Stent-
ing of High Risk Extracranial Lesions Trial with Emboli
Removal) trial; 2, the Cordis carotid stent trial (later be-
came the SAPPHIRE [Stenting and Angioplasty with Pro-
tection in Patients at High Risk for Endarterectomy] trial),
with the Angioguard Filter and the PRECISE carotid stent
(Cordis, Warren, NJ); and 3, the ArteriA US phase 1
clinical trial (Parodi Anti-Embolization System [PAEC],
ArteriA, San Francisco, Calif) and the carotid Wallstent.
Each protocol was approved by the institutional review
board, and written informed consent was obtained from
each patient. Inclusion criteria was50% stenosis for symp-
tomatic patients and 80% for asymptomatic patients in
each protocol. The Cordis Angioguard/PRECISE stent
protocol was for patients at high surgical risk, and the
remaining two protocols had broader inclusion criteria that
allowed enrollment of patients at good surgical risk. How-
ever, as described subsequently, most patients who under-
went treatment with CAS were considered either to have
inoperable conditions or to be at high risk for CEA. In
brief, high risk was defined as patients having one or more
of the following anatomic characteristics: 1, restenosis after
previous CEA; 2, lesion located above C2 or below the
clavicle; 3, hostile neck (previous radical neck dissection,
radiation therapy, presence of a permanent tracheostomy,
frozen neck); or 4, tandem lesions within the same carotid
artery or contralateral internal carotid artery (ICA) occlu-
sion or the following comorbid conditions. These conditions
included: 1, classification III or IV angina or congestive heart
failure; 2, severe chronic obstructive pulmonary disease
(forced expiratory volume,1); or 3, cardiac disease necessi-
tating open heart surgery within 4 weeks. Analysis was on an
intent-to-treat basis. All patients were enrolled solely on the
basis of clinical indication, and no patient was excluded
from the study on the basis of intraoperative angiographic
finding unless the carotid stenosis proved to be below the
treatment threshold (three patients). Patient enrollment
into each protocol was at the discretion of the operator.
During the same period, 120 patients underwent CEA
at our institution, and therefore the interventional cohort
(N  31) represents 20% of the overall patient population
undergoing treatment for carotid artery disease. Of the 31
patients enrolled into the study, 16 (50%) were at anatomic
high risk for CEA: previous CEA, hostile neck (radical neck
dissection, radiation, permanent tracheostomy), frozen
neck, or high or low lesion (lesion above C2 or below the
clavicle). Eleven patients (35%) had severe medical comor-
bidities that would have increased the risk of CEA and
general anesthesia. Twenty patients (65%) were referred by
vascular surgeons for CAS. Fourteen (45%) were deemed to
have inoperable conditions, and 13 (42%) were considered
to be at increased risk for CEA. Four patients were at good
risk for CEA but were treated with CAS because of patient
preference. Demographics and clinical profiles of the pa-
tients are summarized in Table I.
Carotid stent protocol. All patients were seen by a
protocol neurologist before each procedure, and baseline
neurologic functions were evaluated. Either brain com-
puted tomographic (CT) scan or magnetic resonance im-
aging (MRI) was taken before surgery in each case. Twen-
ty-seven patients received clopidogrel bisulfate (75 mg/d)
and aspirin (325 mg/d) for 3 days before the intervention.
Four patients, who did not undergo premedication, had a
loading dose of clopidogrel bisulfate (300 mg) before the
intervention.
Table I. Clinical profile of patients (N  31)
No. (%)
Men 22 (71)
Women 9 (29)
Symptoms (stenosis 50%) 18 (58)
No symptoms (stenosis 80%) 13 (42)
Degree of stenosis (mean  SD) 85%  12%
Age (mean  SD; y) 71  8
Referral by vascular surgeon 20 (65)
CAD 18 (58)
HTN 26 (84)
Recent CHF 4 (13)
Need for open heart surgery
within 30 days
3 (10)
Diabetes mellitus 11 (35)
Tobacco abuse 13 (42)
COPD 3 (10)
Previous CEA 6 (20)
Hostile neck* 6 (20)
High/low lesion 4 (13)
Contralateral ICA occlusion 3 (10)
*Radical neck dissection (n 4), radiation therapy (n 5), immobile spine
(n  1), permanent tracheostomy (n  1).
High/low lesion, lesion above C2 or below clavicule.
CAD, Coronary artery disease; HTN, hypertension; Recent CHF, conges-
tive heart failure within 6 months; COPD, chronic obstructive pulmonary
disease.
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Baseline angiogram. Each patient was brought to the
operating room without a diagnostic angiogram, except
two patients who had an angiogram performed by their
referring physician, and a full cervical and intracranial an-
giogram with at least three vessel studies (bilateral carotids,
unilateral vertebral artery) was obtained just before the
CAS. All patients were awake during the procedure, and
sedation was not used because of impairment of the intra-
procedural neurologic evaluation. In each case, the
OEC/GE Model 9800 mobile C-arm (OEC, Salt Lake
City, Utah) was used. A 125-cm 5F selective Vitek catheter
(Cook, Inc, Indianapolis, Ind) and a 0.038-in Glidewire
(Meditech, Boston Scientific Corp) were used for selective
carotid/cerebral angiography. After selective catheteriza-
tion, a magnified “worst-view” angiogram of the lesion was
taken. Angiographic assessment of degree of stenosis was
determined with the North American Symptomatic Ca-
rotid Endarterectomy Trial criteria of comparison of the
smallest diameter at the lesion with a reference diameter of
the distal ICA in a segment with parallel walls.2
Procedural detail for PercuSurge Medtronic
GuardWire and carotid Wallstent. After confirmation
that the lesion was in the ICA, 70 to 100 IU/kg of heparin
was administered to raise the activated clotting time to
more than 250 seconds. The Glidewire (Medi-Tech/Bos-
ton Scientific, Natick, Mass) and subsequently the Vitek
catheter (Cook, Inc, Bloomington, Ind) were introduced
into the external carotid artery (ECA) ipsilateral to the
target ICA. The Glidewire was exchanged to an Amplatz
superstiff wire (Medi-Tech/Boston Scientific), and the
Vitek catheter and the 5F femoral sheath were withdrawn.
Then a 6F or 7F Shuttle sheath (Cook, Inc) was inserted
over the Amplatz superstiff wire. A cervical carotid angio-
gram was repeated, usually in the lateral view. The balloon
protection system (GuardWire, PercuSurge) consisted of a
0.014-in guidewire with a central lumen connected to a
compliant distal occlusion balloon (Fig 1, A). Nominal
balloon diameters were 5 to 6 mm. After a test for integrity,
the balloon was fully deflated and introduced into the
Shuttle sheath. Then, a predilatation angioplasty balloon (4
mm  4 cm; Savvy, Cordis, or Gazelle, Boston Scientific
Corp) was loaded on to the GuardWire and kept just below
the lesion. Then, the GuardWire was advanced across the
lesion, and the protection balloon was inflated until vessel
size was reached. In cases where the stenosis was extremely
tight, a 2-mm coronary balloon was used to predilate the
lesion before GuardWire insertion. If severe tortuosity was
found in the lesion or within the distal ICA that precluded
insertion of the GuardWire, a separate “buddy wire”
(0.014-in Reflex or Stabilizer, Cordis) was placed across the
lesion to straighten the vessel and facilitate insertion of the
GuardWire (Figs 2 and 3). An angiogram was obtained for
verification of complete occlusion of the ICA. The predila-
tation balloon that was kept within the Shuttle sheath then
was advanced across the lesion, and angioplasty was per-
formed at 5 atm. An appropriately sized Wallstent (8  20
mm or 10  20 mm) was placed. Postdilatation was rou-
tinely performed with a 5 mm  2 cm balloon at 8 to 10
atm. If bradycardia (30/min) or hypotension (90 mm
Hg) was encountered, atropine (1 mg) or phenylephrine
(50-100 g) was administered. After postdilation, the Per-
cuSurge Export aspiration catheter was introduced to aspi-
rate the blood column and the embolic particles. Finally,
the distal occlusion balloon was deflated, and a completion
angiogram, including biplane cervical carotid and intracra-
nial views, was obtained.
Procedural detail for Cordis Angioguard and PRE-
CISE stent. The 6F Shuttle sheath was advanced into the
common carotid artery (CCA) as described previously.
With lateral projection, the Angioguard filter with a diam-
Fig 1. Three different types of cerebral protection devices used in this study. A, PercuSurge GuardWire.
B, Angioguard filter. C, PAEC.
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eter matching the distal cervical ICA was advanced through
the lesion (Fig 1, B , and Figs 4 and 5) Then, the outer
sheath of the Angioguard filter was retrieved and the filter
was deployed. Predilatation before Angioguard filter pas-
sage or use of a second buddy wire was used as described
previously. An angiogram was obtained to confirm correct
positioning of the filter and preservation of prograde ICA
flow. Predilatation was performed as described previously.
Then, an appropriately sized Cordis PRECISE stent was
deployed across the lesion, and postdilatation was per-
formed. A retrieval catheter then was introduced over the
wire of the Angioguard filter, and the filter was collapsed
and then retrieved. Completion arteriography was per-
formed.
Procedural detail for ArteriA PAEC and carotid
Wallstent. Instead of the Shuttle sheath, the PAEC was
introduced into the CCA over a superstiff wire placed into
the ECA as described previously (Figs 1, C, and Fig 6). The
Parodi External Carotid Balloon (PEB) was introduced
through the main lumen of the PAEC into the ECA.
Finally, a 5F sheath was percutaneously inserted in the
contralateral femoral vein and connected to the Parodi
Blood Recovery System. This system had a filter to capture
the emboli (Fig 7). After completion of these steps, a
0.014-in standard guidewire and a predilatation balloon
were inserted through the PAEC and kept just below the
lesion. The occlusion balloon that was attached at the distal
end of the PAEC and the PEB was inflated to occlude
prograde flow of the CCA and retrograde flow from the
ECA. Finally, the proximal end of the PAEC was connected
to the femoral vein through the Parodi Blood Recovery
System. Contrast was injection into the ICA, and reversal of
flow in the ICA was confirmed. The guidewire that was
positioned inside the PAEC then was used to traverse the
lesion, and angioplasty and stenting was performed with
the Carotid Wallstent. Both the PEB and the PAEC bal-
loon were deflated at the completion of the procedure.
Neurologic evaluation. During the procedure, the
patient’s neurologic status was monitored every 4 to 5
minutes by the surgeon with: 1, talking to the patient; and
2, having the patient squeeze a toy that was placed in the
appropriate hand. If the patient did not tolerate balloon
occlusion of either the ICA or the CCA, use of intermittent
occlusion was part of the protocol. Within 24 hours after
CAS, each patient was examined by the protocol neurolo-
gist who also had evaluated the patient before the interven-
tion. Any neurologic change was recorded. Neurologic
evaluation was also performed 1, 6, and 12 months after the
procedure and yearly thereafter. If any change in neuro-
logic status was found, either a brain CT scan or a MRI was
obtained.
Fig 2. A 75-year-old male patient treated with Percusurge GuardWire and Wallstent. This patient had classification IV
unstable angina and therefore was referred for CAS before undergoing coronary artery bypass grafting. This patient was
only patient with periprocedural stroke. A, Preprocedure angiogram showed high-grade ICA stenosis with moderate
tortuousity of lesion. B, Passage of GuardWire (p) was not possible because of tortuousity. C, Separate buddy wire (b)
was used to straighten artery before passing of GuardWire. D, Cerebral protection was confirmed with angiogram. E,
Completion angiogram showed satisfactory result. Note that stent has straightened ICA.
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Postprocedural follow-up. Electrocardiogram and
myocardial enzymes were checked immediately after the
procedure and at 24 hours in each patient to rule out acute
myocardial infarction. Each patient was seen by the sur-
geon, and carotid duplex scan was obtained at 1, 6, and 12
months after the procedure and yearly after.
RESULTS
One procedure (3%) was considered a technical failure
from the inability to cross the lesion with a guidewire. This
patient had a preocclusive lesion in the right ICA. In
addition, the ICA took off at an acute angle from the
bifurcation and made the passage of the guidewire impos-
sible or risky; therefore, the procedure was aborted. This
patient was considered to be “inoperable” because of re-
cent congestive heart failure, oxygen-dependant chronic
obstructive pulmonary disease, and severe thrombocytope-
nia and therefore was treated conservatively. This patient
did not have a neurologic event during the follow-up
period.
Technical success was achieved in the remaining 30
cases (97%) with satisfactory results (residual stenosis,
10%). One patient had dissection of the CCA during the
insertion of the Shuttle sheath. After completion of the ICA
stenting, this dissection was successfully treated with stent-
ing (Fig 5). Patency of the ECA was documented after
stenting in each case. However, a compromise (50%
stenosis) was seen in the ECA in four cases (13%). Each
protection device added extra steps to the standard CAS
and was accompanied with several technical problems (Ta-
ble II). However, none of these procedural events resulted
in serious sequale but one. All patients tolerated the pro-
tection well, and no instances were seen where the protec-
tion had to be terminated. All femoral puncture sites were
managed with manual compression after the activated clot-
ting time returned to the preprocedural level, and no
instance of groin hematoma was seen. As a result of balloon
angioplasty of the carotid bulb, three patients had temporal
asystole and six had bradycardia (30 bpm). Of these nine
patients, eight had hypotension (90 mm Hg). Four pa-
tients had bradycardia in the range of 31 to 59 bpm, but
none needed treatment. Hypotension was persistent in four
of the eight patients with hypotension and necessitated 4 to
12 hours of intravenous phenylephrine; all of these patients
needed stay in the intensive care unit after the procedure.
An additional three patients needed intensive care unit stay,
and 23 patients (77%) did not. The average length of
hospital stay was 3.4  8.1 days and included the patient
who had coronary artery bypass grafting after CAS (33
days, from pneumonia after coronary artery bypass graft-
ing) and a patient with a major stroke (35 days). The
Fig 3. A 57-year-old male patient with symptomatic right ICA stenosis. This patient had immobile spine from
spondylosis and was considered to have inoperable condition. A, Preprocedure angiogram revealed preocclusive lesion.
B, Cerebral protection achieved with distal occlusion balloon (p) C, Completion angiogram showed satisfactory result.
Note focal dilatation (d) at site where occlusion balloon was deployed. D, Follow-up angiogram obtained 12 months
after procedure showed severe instent restenosis. E, Balloon angioplasty was performed with cerebral protection with
satisfactory results.
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average length of hospital stay without these two patients
was 1.3 0.7 days. The patient with a major stroke also had
myocardial infarction (non–Q wave) 2 weeks after surgery,
and no death occurred.
Periprocedural neurologic outcome. One patient
(3%) had neurologic complications after CAS (Fig 2). This
patient had high-grade right ICA stenosis and 70% left ICA
stenosis, both of which were asymptomatic. Because the
patient had unstable angina, he was enrolled into the Per-
cuSurge/Boston Scientific Corporation protocol. Because
of the tortuousity (90 degrees) of the ICA, the PercuSurge
GuardWire could not be passed through the lesion. This
was from the abrupt change in the stiffness between the
floppy tip and the occlusion balloon. A buddy-wire tech-
nique was used. The patient had good intracerebral collat-
eral filling via a patent anterior communicating artery and
tolerated the procedure and the ICA occlusion well. His
condition was neurologically intact during and immediately
after the procedure. Completion angiogram showed a
widely patent stent, and intracranial angiogram failed to
show any evidence of embolization. However, 2 hours after
the procedure, the patient had a major stroke (National
Institutes of Health scale score, 6). Brain CT scan showed
new cortical and subcortical infarcts in the right middle
cerebral artery distribution. This patient subsequently un-
derwent intubation for aspiration pneumonia and then had
a non–Q wave myocardial infarction. The overall 30 day
stroke/death rate was 3%.
Follow-up. No patient was lost to follow-up. During
a mean follow-up period of 17.3 8.5 months, one patient
had subacute thrombosis of the stent at 3 weeks and three
patients (13%) had restenosis on the basis of follow-up
duplex scanning (Table III). The patient with subacute
thrombosis was undergoing dual antiplatelet therapy. This
patient did not have a stroke. Two patients needed repeat
angioplasty with PercuSurge brain protection at 12 months
after CAS for 90% asymptomatic instent stenosis (Fig 3).
One patient died at 12 months of preexisting congestive
heart failure.
Follow-up neurologic outcome. During the fol-
low-up period, one patient had a single episode of amurosis
fugax ipsilateral to the CAS at 24 months after stenting.
The symptom resolved within several minutes. Duplex scan
showed a widely patent stent with no signs of restenosis. No
patient had a stroke during the follow-up period.
DISCUSSION
CAS has emerged as an alternative for CEA in the
treatment of significant carotid artery stenosis.9-15 Al-
though its use in patients at high surgical risk appears
reasonable, CAS has not received wide acceptance for pa-
tients at good surgical risk because of the availability of
CEA with its excellent results and also because of the risk of
embolic stroke associated with CAS.2-6,16-23 Experimental
and clinical studies have shown the risk of embolization
associated with carotid stenting that has been the Achilles’
Fig 4. A 70-year-old male patient treated with Angioguard filter and PRECISE stent. This patient had high lesion and
history of repeat congestive heart failure and was considered at poor risk for CEA. A, Preprocedure angiogram showed
preocclusive symptomatic stenosis at level of C2. B, Predilatation of lesion with 2-mm balloon (p) was necessary before
passage of Angioguard filter. Note filter was kept in ECA while predilatation was performed. C, Completion angiogram
showed satisfactory result.
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heel of this procedure. In our ex vivo carotid stenting
model, macroscopic emboli were produced from each
plaque that was stented.24 Jordan et al28 studied the inci-
dence of intraprocedural embolization with transcranial
Doppler scan. The authors showed that CAS was accom-
panied by four-fold higher rates of high-intensity transcra-
nial signals (HITS) compared with CEA. In their study,
higher rate of HITS translated into higher rate of periop-
Fig 5. A 74-year old female patient with history of radical neck dissection and radiation with permanent tracheostomy.
A, Preprocedure arch angiogram showed deep take off of left CCA. B, During passage of 6F sheath, dissection was
caused in left CCA from vessel tortuousity. Note complete obliteration of flow. C, Stent was placed in proximal left
CCA to repair dissection. D, Angiogram revealed irregular plaque. Note excellent flow through filter (f). E,
Angioplasty and stenting was perfomed with filter protection (f). F, Completion angiogram showed satisfactory results.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 6 Ohki et al 1181
erative neurologic events. These findings were also con-
firmed in other studies that evaluated CAS with transcranial
Doppler scan.29 A recent study evaluated 70 unprotected
CAS procedures with diffusion weighted MRI performed
before and after CAS.30 Although only one patient had a
perioperative stroke, diffusion-weighted MRI showed new
embolic lesions in 29% of patients who underwent CAS.
That CAS produces a significant amount of embolic
particles is not surprising in light of the fact that carotid
stenosis is an emboli-producing lesion, unlike most coro-
nary or peripheral lesions, where flow limitation from the
obstruction is the primary problem. For this reason embolic
lesions have traditionally been considered a contraindica-
tion for endovascular therapy.31 Although acceptable re-
sults of CAS without the use of brain protection have been
reported by several authors, a number of studies showed
the contrary, with high periprocedural neurologic compli-
cation rates.29,32,33 For example, the Leicester trail, which
randomized severe symptomatic carotid stenosis to CEA
and CAS, was prematurely terminated after enrollment of
17 patients.29 Of note is the fact that this trial had no
exclusion criteria and that all patients with symptomatic
severe stenosis were enrolled. Five of the seven patients
treated with unprotected CAS had a periprocedrual neuro-
logic event, and none of the 10 patients treated surgically
had complications. Although some have criticized the va-
lidity of this study because of a lack of adequate safeguards
and operator experience,34 it nonetheless underscores the
risk of embolization during CAS. The Wallstent Trial was
another randomized prospective study (CEA versus CAS)
that was terminated after enrollment of 219 symptomatic
patients. The 30-day periprocedure combined endpoint
(any stroke and death) was 4.5% for CEA and 12.1% for
unprotected CAS.32 The author concluded that CAS with-
out an embolic protection device was not equivalent to
CEA with respect to safety. Two additional randomized
trials have been completed and published. These include
the Carotid and Vertebral Artery Transluminal Angioplasty
Study trial and the Brooks trial. Contrary to the previously
mentioned trials, both trials showed that CAS without
protection was equivalent to CEA in terms of perioperative
stroke and death rate.14,15
Brain protection was first conceptualized by Theron et
al,25 who performed the first clinical case. Their seminal
work, along with convincing experimental and clinical evi-
dence that showed that embolization is a significant risk
associated with CAS, led to the development of a number
of protection devices.24,28-30 Although no randomized
trials show benefit of such protection devices for CAS,
several studies have shown the safety and possible efficacy of
Fig 6. A 74-year-old female patient with high lesion was treated with ArteriA protection and Carotid Wallstent.
Patient was considered at high risk for CEA because of high lesion (C2). A, Preprocedural angiogram showed
high-grade ICA stenosis and severe tortuousity of distal ICA. Because tortuosity would pose significant technical
challenge for distal protection devices, Parodi device was used. B, CCA and ECA occlusion balloons were inflated.
Proximal end of PAEC was then connected to sheath placed in femoral vein to create temporal arteriovenous shunt
between ICA and femoral vein. C, Reversal of flow was confirmed with injection of contrast into ICA. D, Because of
arteriovenous shunt, injected contrast returned toward catheter, thereby making it impossible for emboli to flow to
brain. E, Completion angiogram shows satisfactory result.
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protection devices.26,35-37 This study confirms these find-
ings and shows that protection devices can be used safely.
Of note is the fact that our series enrolled every patient
solely on the basis of clinical indications and none were
excluded on the basis of angiographic findings. These pa-
tients, therefore, represent “real” patients with no selection
bias. In view of this, we believe that the periprocedural
stroke/death rate of 3% is acceptable and encouraging.
Although the clinical benefit of recovering emboli from the
brain has not been proven, the result of the SAFER (Saphe-
nous Vein Graft Angioplasty Free of Emboli Randomized)
trial is relevant. This trial randomized 550 patients with
degenerated saphenous vein graft after coronary artery
bypass grafting to either PercuSurge GuardWire–protected
percutaneous transluminal coronary angioplasty (PTCA)
or unprotected PTCA.38 The 30-day myocardial rate was
16.5% for the control arm and was reduced to 8.4% in the
protected arm (P  .001). On the basis of this trial, the
Fig 7. Emboli captured within Parodi Blood Return System.
Table II. Protection-related procedural details
GuardWire Angioguard PAES
Need for predilatation* 1/19 2/7 (28%) 0/4
Need for buddy wire 2/19 (11%) 0/7 0/4
Spasm at protection site 4/19 (21%) 2/7 (28%) 0/4
Intolerance 0/19 0/7 0/4
Neurologic complication 1/19 (5%) 0/7 0/4
*Before passing of protection device.
Table III. Stent patency
Stent
Follow-up
period
Degree of
stenosis Symptoms Treatment Outcome
Wallstent 12 mos 90% No Repeat PTA* Successful
Wallstent 12 mos 90% No Repeat PTA* Successful
Wallstent 12 mos 70% No () NA
PRECISE 3 wks 100% No () NA
*With PercuSurge protection.
PTA, Percutaneous transluminal angioplasty; NA, not applicable.
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PercuSurge GuardWire received US Food and Drug Ad-
ministration approval and is currently considered the stan-
dard of care for select patients undergoing PTCA for de-
generated coronary saphenous vein grafts. If prevention of
emboli from reaching the heart is beneficial, one can spec-
ulate that it is also beneficial for the brain. Several random-
ized prospective trials are underway in the United States to
compare CEA with protected CAS, and these trials will
further clarify the role of brain protection.
The intent of this study is not to compare each individ-
ual protection device. However, several observations can be
made. First, the current distal protection devices, whether
balloon or filter, do not perform like a standard guidewire
in terms of torquability and the ability to negotiate narrow
and tortuous lesions because both these protection devices
have an abrupt change in flexibility and a larger crossing
profile at the point where the protection device is attached
to the wire. We encountered one major stroke in our series,
and this occurred in a case where the PercuSurge Guard-
Wire could not traverse the mildly tortuous lesion because
of this abrupt change in stiffness (Fig 2). The manipulation
of the GuardWire or the placement of the buddy wire that
was needed to straighten the vessel to facilitate the passage
of the GuardWire possibly could have caused this embolic
stroke. Overall, 11% of GuardWires and 28% of Angioguard
filters needed either predilatation or placement of a buddy
wire before protection was obtained. Such manipulation of
the lesion has been documented to generate emboli in both
the clinical and the experimental setting and may lessens the
efficacy of the device.37,39 Next generation devices, includ-
ing the PercuSurge GuardWire Plus and Angioguard XP,
have made this transition smoother with a lower profile.
Also, we noticed that keeping the protection device stable
while deployed in the distal ICA was quite difficult. This
coupled with the fact that a certain amount of radial force
was applied to the vessel wall by the balloon or the filter
resulted in spasm of the ICA. However, such a spasm was
always temporary, resolved within 10 to 20 minutes, and
did not result in clinical sequelae. Other investigators have
also raised concern regarding the efficacy of distal protec-
tion devices.26,40 Mathias41 has reported that although
brain protection reduced the perioperative stroke rate by
60% compared with unprotected CAS, 10% of patients who
underwent protected CAS had silent infarcts on the basis of
diffusion-weighted MRI. The authors postulate that parti-
cles that were dislodged during protection device passage
or those that flowed through the filter or around the filter
were responsible for these findings. As far as the efficacy of
capturing emboli, the ArteriA device probably has the most
promise because brain protection can be obtained before
any manipulation of the lesion and particles of all sizes can
be effectively captured with the flow reversal. In addition,
the fact that one can use a guidewire of choice and that
there is no need to keep the wire extremely stable made the
procedure easier. The need for a larger groin puncture
(10F) may be a weakness of this device, although the
magnitude of a groin complication is not equal to that of a
neurologic complication.
Three of the 30 treated patients had restenosis. This is
contrary to those who believe that restenosis is not an issue
with CAS35 but is in accordance with two studies that were
recently presented.33,42 However, in our series, restenosis
did not result in clinical sequelae and was also treatable with
repeat angioplasty. The true incidence rate of restenosis is
still unclear, but with drug eluting stents with promising
early outcome on the horizon, we believe that it should not
be another Achilles’ heel of CAS.
In conclusion, CAS with various types of brain protec-
tion is feasible and can be performed without adding exces-
sive complexity to the procedure. It can also be performed
safely and effectively in an operating room setting with a
mobile C-arm. Each device has unique strengths and weak-
nesses, but all performed well in our experience. Although
the comparative value of CAS for patients at good risk
remains unclear, brain-protected CAS appears to be an
acceptable alternative for selected groups of patients who
are poor surgical candidates.
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